Target Protein and E3 Ubiquitin Ligase (POI-E3)

The "Target Protein and E3 Ubiquitin Ligase" refers to the functional ternary complex formed by a Proteolysis Targeting Chimera (PROTAC) or a molecular glue, which recruits an E3 ubiquitin ligase to a specific protein of interest (POI) [1, 2]. This induced proximity allows the E3 ligase to catalyze the transfer of ubiquitin molecules onto the target protein, marking it for recognition and degradation by the 26S proteasome [4, 13]. Unlike traditional inhibitors that require high-occupancy binding to an active site, this mechanism is event-driven and catalytic, meaning a single degrader molecule can induce the destruction of multiple target proteins [2, 5]. This technology is highly effective for targeting proteins previously considered "undruggable," such as transcription factors, scaffolding proteins, and those with mutations that confer resistance to traditional inhibitors [3, 11]. Therapeutic development is most advanced in oncology, targeting proteins like the androgen receptor (AR) and estrogen receptor (ER), but the platform is also being explored for neurodegenerative diseases and inflammatory conditions [5, 12]. Key pharmacological considerations include the "hook effect," where high concentrations of the bifunctional molecule prevent ternary complex formation, and the potential for resistance through the downregulation or mutation of the recruited E3 ligase machinery [7, 8].

Other names

Ternary complexPOI-PROTAC-E3 complexTargeted protein degradation complexDegrader complex

Targeted protein degradation (TPD) via the induction of proximity between a protein of interest (POI) and an E3 ubiquitin ligase, facilitating polyubiquitination and subsequent degradation by the 26S proteasome.